Cost-effectiveness analysis of the combination of enfortumab vedotin and pembrolizumab in first-line treatment of previously untreated advanced urothelial carcinoma

LI Xin-xin, MOU Hong-li, LI Si-chen, WANG Shu-lin

PDF(1046 KB)
PDF(1046 KB)
Chinese Journal of New Drugs ›› 2026, Vol. 35 ›› Issue (17) : 1898-1904. DOI: 10.20251/j.cnki.1003-3734.2026.17.014

Cost-effectiveness analysis of the combination of enfortumab vedotin and pembrolizumab in first-line treatment of previously untreated advanced urothelial carcinoma

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2026, 35(17): 1898-1904 https://doi.org/10.20251/j.cnki.1003-3734.2026.17.014

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1046 KB)

Accesses

Citation

Detail
Sections
Recommended
Total:
Copyright © Chinese Journal of New Drugs, All Rights Reserved.
Tel: 010-52722697 | 010-52723707
　 Powered by Beijing Magtech Co., Ltd.

/

〈 〉